<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191746</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102178</org_study_id>
    <secondary_id>1R01HL141213-01</secondary_id>
    <nct_id>NCT04191746</nct_id>
  </id_info>
  <brief_title>BEST vCLI Registry</brief_title>
  <acronym>BEST</acronym>
  <official_title>BEST Critical Limb Ischemia (vCLI) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For subjects with critical limb ischemia, identify patient, physician/hospital, and
      geographic factors associated with variations in treatment strategies; compare treatments and
      outcomes, including quality of life, cost and cost effectiveness, at 6, 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Percentage of participants with major adverse limb events (MALE) as measured by patient reports (verified by medical records)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants in the registry with major limb events as reported by participants and confirmed by medical records</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with major adverse limb events (MALE) as measured by patient reports (verified by medical records)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants in the registry with major limb events as reported by participants and confirmed by medical records</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants that died within 30 days of index procedure</measure>
    <time_frame>30 days</time_frame>
    <description>Collect composite of MALE or perioperative death within 30 days of index procedure using patient/proxy information qualified by medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with amputation free survival as measured by patient report/verified by medical record review</measure>
    <time_frame>6 months</time_frame>
    <description>Interviews completed at 6 months with participants that note no hospitalization for amputation and verified by medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with amputation free survival as measured by patient report/verified by medical record review</measure>
    <time_frame>12 months</time_frame>
    <description>Interviews completed at 12 months with participants that note no hospitalization for amputation and verified by medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that did not have secondary interventions in index leg as measured by patient report/verified by medical record review</measure>
    <time_frame>6 months</time_frame>
    <description>At 6 month visit, the number of participants that did not report additional procedures such as surgery or angiography.in the affected leg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that did not have secondary interventions in index leg as measured by patient report/verified by medical record review</measure>
    <time_frame>12 months</time_frame>
    <description>At 12 month visit, the number of participants that did not report additional procedures such as surgery or angiography.in the affected leg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of interventions per limb as measured by patient report/verified by medical record review</measure>
    <time_frame>6 months</time_frame>
    <description>Interventions consist of need to be hospitalized for a form of revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of interventions per limb as measured by patient report/verified by medical record review</measure>
    <time_frame>12 months</time_frame>
    <description>Interventions consist of need to be hospitalized for a form of revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that did not have limb revascularization failure as measured by patient report/verified by medical record review</measure>
    <time_frame>6 months</time_frame>
    <description>Limb revascularization failure is loss of circulation to the limb that has procedural revascularization previously performed that is non functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that did not have limb revascularization failure as measured by patient report/verified by medical record review</measure>
    <time_frame>12 months</time_frame>
    <description>Limb revascularization failure is loss of circulation to the limb that has procedural revascularization previously performed that is non functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who did not have a myocardial infarction as measured by patient report/verified by medical record review</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants that answered no to the question &quot;Was your hospitalization for a Heart Attack(MI) at 6 months verified by medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who did not have a myocardial infarction as measured by patient report/verified by medical record review</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants that answered no to the question &quot;Was your hospitalization for a Heart Attack(MI) at 12 months verified by medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who did not have a stroke while in the registry as measured by patient report/verified by medical record review</measure>
    <time_frame>6 months</time_frame>
    <description>Stroke is inclusive of a cerebral vascular including a ischemic, hemorrhagic or a TIA event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who did not have a stroke while in the registry as measured by patient report/verified by medical record review</measure>
    <time_frame>12 months</time_frame>
    <description>Stroke is inclusive of a cerebral vascular including a ischemic, hemorhagic or a TIA event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that did not have a periprocedural (30 day) major adverse cardiac events as measured by patient report/verified by medical record review</measure>
    <time_frame>6 months</time_frame>
    <description>Events that occur during a revascularization procedure including cardiovascular events such as Myocardial Infarction and stoke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measure by the validated QOL tool called the EuroQol that will be administered throughout the study</measure>
    <time_frame>Baseline</time_frame>
    <description>The EuroQol is a 6 question validated instrument that asks questions regarding mobility, self care, usual activities, pain/discomfort and anxiety and depression. I also includes a 0-100 scale regarding participants assessment of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measure by the validated QOL tool called the EuroQol that will be administered throughout the study</measure>
    <time_frame>6 month</time_frame>
    <description>The EuroQol is a 6 question validated instrument that asks questions regarding mobility, self care, usual activities, pain/discomfort and anxiety and depression. I also includes a 0-100 scale regarding participants assessment of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measure by the validated QOL tool (EuroQol) that will be administered throughout the study</measure>
    <time_frame>12 month</time_frame>
    <description>The EuroQol is a 6 question validated instrument that asks questions regarding mobility, self care, usual activities, pain/discomfort and anxiety and depression with a range of 5 answers. I also includes a 0-100 scale regarding participants assessment of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the the SF-12 instrument that will be administered throughout the study</measure>
    <time_frame>Baseline</time_frame>
    <description>The SF-12 Health Survey is a shorter version of the SF-36 Health Survey that uses 12 questions to measure functional health and well-being from the patient's point of view</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the the SF-12 instrument that will be administered throughout the study</measure>
    <time_frame>6 months</time_frame>
    <description>The SF-12 Health Survey is a shorter version of the SF-36 Health Survey that uses 12 questions to measure functional health and well-being from the patient's point of view</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the the SF-12 instrument that will be administered throughout the study</measure>
    <time_frame>12 months</time_frame>
    <description>The SF-12 Health Survey is a shorter version of the SF-36 Health Survey that uses 12 questions to measure functional health and well-being from the patient's point of view</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Participants with critical limb disease</arm_group_label>
    <description>This registry will collect data from participants with critical limb disease from Duke University and approximately 40 sites in North America.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with critical limb ischemia Phase I: While the BEST-CLI Trial is
        actively enrolling, the BEST-Registry will only enroll patients who first screen fail from
        BEST-CLI.

        Phase II: After BEST-CLI officially finishes enrollment, screen failure for BEST-CLI will
        no longer be required for enrollment into the BEST-Registry

        1200 patients, across approximately 40 sites participating in BEST-CLI clinical trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  age 18 years or older

          -  Infrainguinal peripheral artery disease (occlusive disease of the arteries below the
             inguinal ligament)

          -  Critical limb ischemia, defined as arterial insufficiency with gangrene, non-healing
             ischemic ulcer, or rest pain consistent with Rutherford categories 4-6

          -  Documented consideration for enrollment in the BEST-CLI Trial with documented failure
             to meet inclusion / exclusion criteria. Phase ll After BEST CLI official enrollment
             ends, this inclusion criteria will be removed.

          -  Willingness to comply with vCLI protocol, attend follow-up appointments, complete all
             study assessments, and provide written informed consent.

        Exclusion Criteria:

          -  Presence of a popliteal aneurysm (&gt; 2 cm) in the index limb

          -  Life expectancy of less than 2 years due to reasons other than peripheral artery
             disease

          -  Active vasculitis, Buerger's disease, or acute limb-threatening ischemia

          -  Current chemotherapy or radiation therapy

          -  Pregnancy or lactation

          -  Administration of an investigational drug for peripheral artery disease within 30 days
             of randomization

          -  Participation in a clinical trial (except observational studies) within the previous
             30 days

          -  Prior enrollment or randomization into the BEST-CLI trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manesh Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sreekanth Vemulapalli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura A Drew, BSN</last_name>
    <phone>919-668-8892</phone>
    <email>laura.drew@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khaula Baloch, MPH</last_name>
    <phone>919-668-8909</phone>
    <email>khaula.baloch@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Cox, MD</last_name>
      <email>socrvascularreseach@dm.duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

